Date: 2022-03-30

Type of information: Licensing agreement

Compound: apraglutide

Company: Vectivbio (Switzerland) Asahi Kasei Pharma (Japan)

Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation

Type agreement: licensing

Action mechanism: GLP-2 analog This next-generation, long-acting synthetic GLP-2 analog is being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).

Disease: short bowel syndrome with intestinal failure (SBS-IF), acute graft-versus-host disease (aGVHD)


  • On March 30, 2022, VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has entered into an exclusive licensing agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure (SBS-IF), steroid-refractory acute graft-versus-host disease (aGVHD) and future indications in Japan.

Financial terms: Under the terms of the agreement, VectivBio will receive an upfront cash payment of approximately $30 million ($5 million of which is the first installment of Asahi Kasei Pharma’s development cost-sharing) and eligibility for up to approximately $170 million in milestone payments if certain development, regulatory and commercial events are achieved. VectivBio is also eligible to receive tiered, double-digit, escalating royalties on sales of apraglutide in Japan. Asahi Kasei Pharma has a right to participate in the development of new indications and lead and fund all development, registration and commercialization activities in Japan.

Latest news:

Is general: Yes